Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Critical Path Will Lead To Device Research Opportunities In ’06 – Woodcock

This article was originally published in The Gray Sheet

Executive Summary

A formal Critical Path priority list to be released in the coming year will include device-focused initiatives, assured FDA Deputy Commissioner for Operations Janet Woodcock
Advertisement

Related Content

People In Brief
People In Brief
People In Brief
Critical Path opportunities list
FDA Budget Request Proposes New User Fee For Facility Reinspections
CDRH 2006 Priorities Reflect Urgency Of Device Postmarket Issues
FDA Clears Third Wave Invader Pharmacogenetic Test
Critical Path Still Critical, But Delayed By Drug Safety Agenda – FDA
Critical Path Still Critical, But Delayed By Drug Safety Agenda – FDA
On FDA Critical Path, Device Industry Demands Independence From Pharma
Advertisement
UsernamePublicRestriction

Register

MT023078

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel